drugset / Trial / NCT03220477
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Phase 1
Active not recruiting
28 enrolled
Memorial Sloan Kettering Cancer Center
Astex Pharmaceuticals, Inc. · collabMerck Sharp & Dohme LLC · collabMirati Therapeutics Inc. · collabStand Up To Cancer · collabVan Andel Research Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of a combination of three drugs, pembrolizumab, guadecitabine and mocetinostat. Pembrolizumab is a drug given by vein and all patients will receive the same dose. Guadecitabine and mocetinostat will be given at different doses to find out what effects, if any, they have on treating your cancer and side effects.
Timeline
- Start
- 2017-08-04
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guadecitabine | Oligonucleotide (other) | — | Subcutaneous |
| Subject | Mocetinostat | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |